What Is Next-Generation Sequencing (NGS) Testing for Cancer?

Next-generation sequencing (NGS) testing for cancer is a laboratory technique that reads large stretches of a tumor’s DNA in a single run, hunting for the specific genetic changes driving that particular cancer. Instead of checking one gene at a time, NGS can scan hundreds of genes simultaneously, identifying mutations, rearrangements, and other alterations that may determine which therapies are most likely to work. The technology has become a cornerstone of precision oncology, and it increasingly shapes treatment decisions for lung, breast, colorectal, and many other cancers.

How NGS Differs from Older Sequencing

Traditional gene-by-gene testing worked like reading a book one page at a time. If a doctor suspected a specific mutation, the lab could look for it. But cancers are complicated, and the number of targetable mutations has grown rapidly. Running separate tests for each gene is slow, expensive, and eats through limited tissue samples. NGS changed this by reading millions of DNA fragments at once, then using software to piece the fragments together and flag abnormalities. What once took days for a small stretch of DNA can now cover the entire genome of complex organisms in a single day, though cancer testing typically focuses on a curated set of genes rather than the whole genome.

What the Test Actually Looks For

An NGS cancer panel does not simply tell you whether cancer is present. It profiles the genetic fingerprint of a tumor that has already been diagnosed, searching for changes that have specific treatment implications. A single panel can detect point mutations (where one DNA letter is swapped for another), small insertions or deletions of genetic material, copy number changes (where a gene is amplified or lost), and gene fusions (where two genes that should be separate get stitched together). One validated clinical panel, for instance, covers 323 genes for mutations and copy number changes plus fusions in 17 additional genes, all from a single sample.¹

The scope of the panel matters. Targeted panels focus on a few dozen to a few hundred genes known to be relevant in cancer. Whole-exome sequencing reads all the protein-coding regions of the genome, and whole-genome sequencing covers everything, including non-coding stretches. For most clinical decisions, a well-designed targeted panel delivers what doctors need at deeper coverage and lower cost than broader approaches. Studies have shown that a mid-size custom panel can match whole-exome and whole-genome sequencing in finding clinically relevant variants while achieving higher sequencing depth and generating fewer ambiguous results.²

Where the DNA Comes From

Most NGS testing in cancer starts with tissue. A biopsy or surgical specimen is fixed in formalin and embedded in paraffin (the standard way pathology labs preserve tissue), and DNA is extracted from those blocks. This works well, but the preservation process can damage DNA, making sequencing harder. Research has found that tissue processed with neutral-buffered formalin yields better-quality DNA than unbuffered alternatives, and that samples older than about seven years may not always be suitable for sequencing.³ Newer lab methods have improved success rates for difficult specimens. One approach using an enzyme called S1 nuclease raised the rate of successful DNA library construction from about 60% to roughly 87% across 223 preserved tissue samples, rescuing dozens of cases that would have otherwise failed.⁴

Not every patient has accessible tissue. A tumor may be in a difficult-to-biopsy location, the patient may be too fragile for a procedure, or the available tissue block may be too old or too small. This is where liquid biopsy enters the picture.

Liquid Biopsy and Circulating Tumor DNA

Tumors shed fragments of their DNA into the bloodstream. These circulating tumor DNA (ctDNA) fragments carry the same mutations as the tumor itself, so sequencing them from a simple blood draw can reveal the cancer’s genetic profile without a surgical procedure.⁵ Liquid biopsy is less invasive, can be repeated easily over time, and avoids some of the sampling bias inherent in cutting a small piece from one part of a tumor.

The trade-off is sensitivity. In a study of patients with advanced non-small cell lung cancer, ctDNA-based NGS detected about 72% of the small variants found by standard tissue testing, and overall conclusions between the two methods agreed in roughly 71% of patients. In most cases where results differed, the discrepancy did not change the treatment decision. But in a small fraction of patients, an actionable mutation was missed in blood that tissue testing would have caught.⁶ Liquid biopsy is already an approved alternative for certain mutations. The FDA has supported blood-based EGFR testing in lung cancer, for example, to guide decisions about specific targeted drugs when tissue is unavailable.⁷

How NGS Guides Treatment Decisions

The most direct clinical payoff of NGS is matching a patient’s tumor mutations to available targeted therapies. Drugs that block specific pathways, such as EGFR, HER2, or ALK, only work if the tumor actually carries the relevant alteration. NGS provides that information in one comprehensive test rather than a series of individual assays.⁸ In lung cancer alone, there are now approved therapies targeting EGFR mutations, ALK fusions, ROS1 fusions, BRAF mutations, KRAS G12C, MET alterations, RET fusions, NTRK fusions, and HER2 mutations. Testing for all of these individually would exhaust the tissue sample and take weeks. NGS handles them in a single run.

Beyond matching mutations to drugs, NGS also helps predict response to immunotherapy. Two biomarkers measured by NGS, microsatellite instability (MSI) and tumor mutation burden (TMB), indicate how likely a cancer is to respond to immune checkpoint inhibitors. Research in colorectal cancer has shown that combining MSI status with TMB gives a more precise picture of the immune environment than either marker alone, potentially identifying additional patients who could benefit from immunotherapy.⁹

Tracking Resistance and Residual Disease

Cancer is not static. Tumors evolve under the selective pressure of treatment, and mutations that confer drug resistance can emerge over time. Repeated NGS testing, especially through liquid biopsy, lets oncologists spot resistance early. In one study of lung cancer patients who developed resistance to the targeted drug osimertinib, NGS of blood samples identified 15 different resistance mechanisms, including new EGFR mutations and amplifications in other genes. Some of these changes were detectable months before the cancer visibly progressed on imaging.¹⁰ Similar monitoring has been demonstrated in breast cancer, where tracking mutation levels in blood samples closely mirrored treatment responses and revealed new resistance mutations as they appeared.¹¹

An especially promising application is detecting minimal residual disease (MRD), the tiny number of cancer cells that may remain after surgery or treatment. In early-stage lung cancer, ultra-deep sequencing of blood samples detected ctDNA in patients who later relapsed, with ctDNA positivity preceding visible recurrence on scans by a median of about 2.8 months. The association with relapse was stark: every patient in whom ctDNA was found after surgery went on to experience recurrence.¹² In osteosarcoma, a study using sequencing depths of over 100,000× found that patients with negative ctDNA after surgery had significantly better event-free survival, with positive ctDNA carrying a hazard ratio above 7 for poor outcomes.¹³ This kind of molecular surveillance may eventually help doctors decide who needs additional chemotherapy and who can safely skip it.

Separating Inherited from Tumor-Only Mutations

Not every mutation found in a tumor arose in the tumor. Some are inherited (germline) variants the patient was born with, including mutations in cancer predisposition genes like BRCA1 and BRCA2. If a lab sequences only the tumor without also sequencing normal tissue from the same patient, it cannot reliably tell the two apart.¹⁴ This distinction matters for multiple reasons: inherited variants have implications for the patient’s family members, and some targeted therapies (like PARP inhibitors for BRCA-mutated cancers) work regardless of whether the mutation is germline or somatic.

Paired tumor-normal sequencing solves this cleanly but costs more and requires a second sample. Computational tools have emerged that can estimate the origin of variants from tumor-only data with high accuracy. One such tool demonstrated over 97% agreement with paired tumor-normal analysis for somatic mutations and over 95% for germline mutations across 18 cancer types.¹⁵ Still, when an inherited cancer syndrome is suspected, most guidelines recommend confirmatory germline testing through a dedicated blood sample.

The Problem of Variants of Uncertain Significance

NGS often turns up mutations that are not clearly harmful and not clearly harmless. These variants of uncertain significance (VUS) are one of the most frustrating outputs of genomic testing. A VUS means the lab found a DNA change, but current knowledge cannot determine whether it drives the cancer or is a benign passenger. For patients and doctors, a VUS creates uncertainty: you cannot act on it, but you cannot ignore it either.¹⁶

Machine learning tools are being developed to help resolve these ambiguous variants. One framework demonstrated precision above 99% for both pathogenic and benign classifications on held-out test data, suggesting that computational reclassification may become increasingly reliable.¹⁷ As databases of known variants grow and AI tools improve, the pool of truly uncertain variants should shrink over time, though it will likely never reach zero.

Turnaround Time and Practical Barriers

Speed matters when a patient is waiting to start treatment. Prolonged turnaround time for NGS results can delay therapy and cause real anxiety.¹⁸ In practice, the time from biopsy to NGS report for lung cancer has been measured at a median of roughly 20 to 22 days, depending on institutional workflow. Reflex testing protocols, where NGS is automatically ordered as soon as a cancer diagnosis is confirmed rather than waiting for the oncologist to request it, have shown modest but statistically significant improvements in turnaround time.¹⁹ Even a few days saved can matter when a patient has an aggressive cancer.

Cost, Value, and the Access Gap

NGS testing is not cheap, but the cost picture depends on what you compare it to. When four or more genes need testing, running a single NGS panel is generally less expensive than ordering individual single-gene assays one after another, especially when you factor in the extra lab time, repeat biopsies, and hospital visits that sequential testing often requires.²⁰

Whether NGS is cost-effective in the broader health-economic sense is a separate question, and the answer is less encouraging. A study modeling genomic profiling for metastatic lung adenocarcinoma found that while NGS-guided treatment improved quality-adjusted survival compared to no profiling, the cost per quality-adjusted life-year exceeded conventional willingness-to-pay thresholds.²¹ In lower-income healthcare settings, the gap widens further. A Thai analysis found that NGS-guided sequential testing for advanced lung cancer was not cost-effective at the country’s standard threshold, while simpler single-gene EGFR testing was.²² These findings reflect the uncomfortable reality that the targeted drugs NGS identifies are often very expensive themselves. The test may be affordable; the treatments it unlocks may not be, depending on where you live and what insurance covers.

Tumor Heterogeneity and Its Limits

One challenge NGS cannot fully solve on its own is tumor heterogeneity. A cancer is not a single population of identical cells. Different regions of the same tumor, and different metastatic sites, can carry different mutations. A biopsy from one spot may miss a resistant subclone lurking elsewhere. Standard NGS analyzes bulk tissue, meaning the results represent an average across millions of cells, potentially masking minority populations that could drive relapse.²³

Single-cell sequencing technologies are being developed to address this, reading the genome or gene expression profile of individual cells rather than the bulk average. These methods have already revealed patterns of intratumoral diversity, immune cell interactions, drug resistance mechanisms, and circulating tumor cell biology that bulk sequencing misses entirely.²⁴ Single-cell approaches remain largely research tools for now, but they are beginning to inform clinical thinking about why some tumors respond to treatment and others do not.

NGS in Pediatric Cancers

Childhood cancers are genetically different from adult cancers in ways that make NGS especially valuable. Adult tumors tend to accumulate many mutations over a lifetime of cell division and environmental exposure. Pediatric cancers typically carry far fewer acquired mutations but a higher proportion of inherited changes in cancer predisposition genes.²⁵ Identifying those germline alterations can affect not just the child’s treatment but also genetic counseling for the entire family. NGS panels designed for pediatric cancers are becoming more common, and their findings have reshaped understanding of which childhood tumors have a hereditary basis.

Long-Read Sequencing and What Comes Next

Current clinical NGS platforms mostly use short-read technology, reading fragments of DNA that are a few hundred base pairs long and then computationally assembling the puzzle. This works well for point mutations and small insertions or deletions but struggles with large structural rearrangements, where big chunks of DNA get flipped, moved, or duplicated. Long-read sequencing platforms, which read fragments tens of thousands of base pairs long, can resolve these complex structural variants that short reads miss. In liver cancers, for instance, long-read sequencing detected substantially more structural variants than a previous short-read study and revealed that the mechanisms generating these rearrangements in tumors were different from those seen in normal inherited variation.²⁶ Long reads can also capture epigenetic information like DNA methylation alongside the sequence itself, adding another layer of data from a single experiment.²⁷

Another frontier is using DNA methylation patterns in cell-free DNA for early cancer screening. Because tumors leave distinctive methylation fingerprints in the bloodstream, researchers are developing blood tests that could detect cancer before symptoms appear. One study using targeted methylation sequencing of plasma identified markers capable of distinguishing colorectal and gastric cancers from benign gastrointestinal conditions and predicting which organ the cancer originated from.²⁸ Multi-cancer early detection tests based on these principles are already in commercial development, though their clinical validation and role in routine screening are still being worked out.

What Patients Think About Genomic Data Privacy

NGS generates vast amounts of deeply personal genetic information, which naturally raises privacy questions. Survey data from cancer patients reveals a nuanced picture. The large majority, around 83%, believe genomic data should be protected, yet only about 13% reported significant personal concern about privacy. Patients worried more about insurance discrimination than employment discrimination, and they trusted research institutions more than government agencies or drug companies to keep their data secure. Most were willing to consent to DNA banking, and more were comfortable sharing de-identified data with outside researchers than identified data.²⁹ The takeaway is that cancer patients generally see the potential benefits of genomic testing as worth the privacy trade-off, but they want clear safeguards, especially against insurance-related consequences.